NorthWest Biotherapeutics Inc (NWBO)

[JerryCampbell]

One threshold is 75m in public float. That is usually defined as market cap excluding closely held shares. I believe this would be as of 12/31/18, and unrelated to recent price action.

I think there is also a revenue threshold, but that seems unlikely to apply to nwbo.

Congress, regulators, and practitioners are all aware of the burden to small public companies in time and cost. Audits are supposed to be scaled appropriately for the size and complexity of the firm.

I see the TDRA process as a neutral event unless the increased audit scrutiny uncovers new problems. Given past issues with internal controls, maybe it helps with accuracy and transparency.